{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Olfactory+Disorders", "query": { "condition": "Olfactory Disorders" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 154, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Olfactory+Disorders&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T21:39:00.570Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00538850", "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Fentanyl sublingual spray", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "INSYS Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2007-10", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2014-03-05", "last_synced_at": "2026-09-02T21:39:00.570Z", "location_count": 1, "location_summary": "Chandler, Arizona", "locations": [ { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538850" }, { "nct_id": "NCT04846010", "title": "Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sequelae of; Infection", "Post Infection Glomerulonephritis", "Post-Infectious Peripheral Neuralgia", "Post-Infectious Disorder (Disorder)", "Post-Infectious Arthritis", "Post-Infectious Polyneuritis", "Post-Infectious Parkinsonism", "Post-Infectious Hypothyroidism", "Post Infectious Osteoarthritis", "Anxiety Disorders", "Depression", "Depression, Anxiety", "Depression, Bipolar", "Insomnia", "GERD", "Gastro Esophageal Reflux", "Hepatitis", "Glomerulonephritis" ], "interventions": [ { "name": "PurWet", "type": "COMBINATION_PRODUCT" }, { "name": "FurFat", "type": "COMBINATION_PRODUCT" }, { "name": "PurApo", "type": "COMBINATION_PRODUCT" }, { "name": "PurPhl", "type": "COMBINATION_PRODUCT" }, { "name": "PurClo", "type": "COMBINATION_PRODUCT" }, { "name": "PurInf", "type": "COMBINATION_PRODUCT" }, { "name": "Smoliv", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "All Natural Medicine Clinic, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 2000, "start_date": "2021-03-01", "completion_date": "2022-10-01", "has_results": false, "last_update_posted_date": "2021-05-26", "last_synced_at": "2026-09-02T21:39:00.570Z", "location_count": 1, "location_summary": "Rockville, Maryland", "locations": [ { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04846010" }, { "nct_id": "NCT07611396", "title": "Crownlands Observing Progression With Neurons Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Alzheimer s Disease", "Mild Cognitive Impairment (MCI)" ], "interventions": [], "intervention_types": [], "sponsor": "Crownlands", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 160, "start_date": "2026-05-19", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-02T21:39:00.570Z", "location_count": 1, "location_summary": "Germantown, Maryland", "locations": [ { "city": "Germantown", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07611396" }, { "nct_id": "NCT06434818", "title": "Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Substance Use Disorders", "Opioid Use Disorder", "Alcohol Use Disorder", "Cocaine Use Disorder", "Methamphetamine-dependence" ], "interventions": [ { "name": "EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance)", "type": "COMBINATION_PRODUCT" }, { "name": "CBOT with olfactory stimulants & OFC tasks", "type": "COMBINATION_PRODUCT" }, { "name": "CBOT Sham", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Evon Medics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 300, "start_date": "2023-07-07", "completion_date": "2025-06-30", "has_results": false, "last_update_posted_date": "2024-05-30", "last_synced_at": "2026-09-02T21:39:00.570Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Rockville, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06434818" }, { "nct_id": "NCT04422275", "title": "Coronavirus Smell Therapy for Anosmia Recovery", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anosmia" ], "interventions": [ { "name": "Budesonide", "type": "DRUG" }, { "name": "High-Concentration Essential Oil", "type": "BEHAVIORAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Low-Concentration Essential Oil", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 0, "start_date": "2021-06-01", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2021-03-02", "last_synced_at": "2026-09-02T21:39:00.570Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04422275" }, { "nct_id": "NCT00010023", "title": "Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-04-05", "last_synced_at": "2026-09-02T21:39:00.570Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00010023" }, { "nct_id": "NCT00897793", "title": "Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Head and Neck Cancer", "Lung Cancer", "Prostate Cancer" ], "interventions": [ { "name": "venipuncture", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2006-01", "completion_date": "2010-07", "has_results": false, "last_update_posted_date": "2013-04-12", "last_synced_at": "2026-09-02T21:39:00.570Z", "location_count": 3, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00897793" }, { "nct_id": "NCT01637194", "title": "Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Colon Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Stage IVA Colon Cancer", "Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Salivary Gland Cancer", "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Colon Cancer", "Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Salivary Gland Cancer", "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Salivary Gland Cancer", "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Tongue Cancer" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2008-11", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2012-07-11", "last_synced_at": "2026-09-02T21:39:00.570Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01637194" }, { "nct_id": "NCT03937869", "title": "Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Bacterial Vaginoses" ], "interventions": [ { "name": "Secnidazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lupin Research Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "FEMALE", "summary": "12 Years to 17 Years · Female only" }, "enrollment_count": 40, "start_date": "2018-11-28", "completion_date": "2020-11-05", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-09-02T21:39:00.570Z", "location_count": 9, "location_summary": "Long Beach, California • Hialeah, Florida • Miami Lakes, Florida + 6 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03937869" }, { "nct_id": "NCT01007630", "title": "A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "Rasagiline", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Parkinson's Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "90 Years", "sex": "ALL", "summary": "Up to 90 Years" }, "enrollment_count": 36, "start_date": "2009-11", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2013-12-02", "last_synced_at": "2026-09-02T21:39:00.570Z", "location_count": 1, "location_summary": "Sunnyvale, California", "locations": [ { "city": "Sunnyvale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01007630" } ] }